96 related articles for article (PubMed ID: 21784955)
41. Pretransplantation soluble CD30 level as a predictor of acute rejection in kidney transplantation: a meta-analysis.
Chen Y; Tai Q; Hong S; Kong Y; Shang Y; Liang W; Guo Z; He X
Transplantation; 2012 Nov; 94(9):911-8. PubMed ID: 23052636
[TBL] [Abstract][Full Text] [Related]
42. Soluble levels of CD27 and CD30 are associated with risk of non-Hodgkin lymphoma in three Chinese prospective cohorts.
Bassig BA; Shu XO; Koh WP; Gao YT; Purdue MP; Butler LM; Adams-Haduch J; Xiang YB; Kemp TJ; Wang R; Pinto LA; Zheng T; Ji BT; Hosgood HD; Hu W; Yang G; Zhang H; Chow WH; Kim C; Seow WJ; Zheng W; Yuan JM; Lan Q; Rothman N
Int J Cancer; 2015 Dec; 137(11):2688-95. PubMed ID: 26095604
[TBL] [Abstract][Full Text] [Related]
43. Presence of CD30(+) and CD30L(+) cells in human placenta and soluble CD30 levels in cord blood are independent of maternal atopy.
Ekström ES; Bengtsson A; Svensson A; Nilsson C; Ostlund E; Sandstedt B; Bremme K; Lilja G; Scheynius A
Placenta; 2001 Apr; 22(4):372-9. PubMed ID: 11286574
[TBL] [Abstract][Full Text] [Related]
44. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection.
Slavcev A; Lácha J; Honsová E; Sajdlová H; Lodererová A; Vitko S; Skibová J; Striz I
Transpl Immunol; 2005 Jun; 14(2):117-21. PubMed ID: 15935302
[TBL] [Abstract][Full Text] [Related]
45. Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies.
Vaidya S; Partlow D; Barnes T; Gugliuzza K
Transplantation; 2006 Dec; 82(12):1606-9. PubMed ID: 17198244
[TBL] [Abstract][Full Text] [Related]
46. Serum and CSF soluble CD26 and CD30 concentrations in healthy pediatric surgical outpatients.
Delezuch W; Marttinen P; Kokki H; Heikkinen M; Vanamo K; Pulkki K; Matinlauri I
Tissue Antigens; 2012 Oct; 80(4):368-75. PubMed ID: 22861386
[TBL] [Abstract][Full Text] [Related]
47. Soluble CD30: a possible serum tumor marker for primary effusion lymphoma.
Michai M; Goto H; Hattori S; Vaeteewoottacharn K; Wongkham C; Wongkham S; Okada S
Asian Pac J Cancer Prev; 2012; 13(10):4939-41. PubMed ID: 23244086
[TBL] [Abstract][Full Text] [Related]
48. Panel reactive HLA antibodies, soluble CD30 levels, and acute rejection six months following renal transplant.
Domingues EM; Matuck T; Graciano ML; Souza E; Rioja S; Falci MC; Monteiro de Carvalho DB; Porto LC
Clin Transplant; 2010; 24(6):821-9. PubMed ID: 20047612
[TBL] [Abstract][Full Text] [Related]
49. sCD30 and sCD40L detection in patients with osteosarcoma, chondrosarcoma and Ewing sarcoma.
Solooki S; Khozaei A; Shamsdin SA; Emami MJ; Khademolhosseini F
Iran J Immunol; 2013 Dec; 10(4):229-37. PubMed ID: 24375064
[TBL] [Abstract][Full Text] [Related]
50. Pre- and post-transplant monitoring of soluble CD30 levels as predictor of acute renal allograft rejection.
Wang D; Wu GJ; Wu WZ; Yang SL; Chen JH; Wang H; Lin WH; Wang QH; Zeng ZX; Tan JM
Transpl Immunol; 2007 Jun; 17(4):278-82. PubMed ID: 17493531
[TBL] [Abstract][Full Text] [Related]
51. Prognostic values of soluble CD30 and CD30 gene polymorphisms in heart transplantation.
Frisaldi E; Conca R; Magistroni P; Fasano ME; Mazzola G; Patanè F; Zingarelli E; Dall'omo AM; Brusco A; Amoroso A
Transplantation; 2006 Apr; 81(8):1153-6. PubMed ID: 16641601
[TBL] [Abstract][Full Text] [Related]
52. Association of serum-soluble CD26 and CD30 levels with asthma, lung function and bronchial hyper-responsiveness at school age.
Remes ST; Delezuch W; Pulkki K; Pekkanen J; Korppi M; Matinlauri IH
Acta Paediatr; 2011 Sep; 100(9):e106-11. PubMed ID: 21401715
[TBL] [Abstract][Full Text] [Related]
53. Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases.
Haque T; Chaggar T; Schafers J; Atkinson C; McAulay KA; Crawford DH
J Med Virol; 2011 Feb; 83(2):311-6. PubMed ID: 21181928
[TBL] [Abstract][Full Text] [Related]
54. Peripheral T lymphocyte cytokine profile (IFNgamma, IL-2, IL-4) and CD30 expression/release during measles infection.
Vinante F; Krampera M; Morosato L; Rigo A; Romagnani S; Pizzolo G
Haematologica; 1999 Aug; 84(8):683-9. PubMed ID: 10457402
[TBL] [Abstract][Full Text] [Related]
55. TH1/TH2 cytokines and soluble CD30 levels in kidney allograft patients with donor bone marrow cell infusion.
Solgi G; Amirzagar AA; Pourmand G; Mehrsai AR; Taherimahmoudi M; Baradaran N; Nicknam MH; Ebrahimi Rad MR; Saraji A; Asadpoor AA; Moheiydin M; Nikbin B
Transplant Proc; 2009 Sep; 41(7):2800-4. PubMed ID: 19765439
[TBL] [Abstract][Full Text] [Related]
56. Post-transplant increased levels of serum sCD30 is a marker for prediction of kidney allograft loss in a 5-year prospective study.
Delgado JC; Pavlov IY; Shihab FS
Transpl Immunol; 2009 Dec; 22(1-2):1-4. PubMed ID: 19772921
[TBL] [Abstract][Full Text] [Related]
57. Serum levels of soluble CD30 in adult patients affected by atopic dermatitis and its relation to age, duration of disease and Scoring Atopic Dermatitis index.
Di Lorenzo G; Gangemi S; Merendino RA; Minciullo PL; Cannavò SP; Martinelli N; Mansueto P; Rini GB; Corrocher R; Pacor ML
Mediators Inflamm; 2003 Apr; 12(2):123-5. PubMed ID: 12775363
[TBL] [Abstract][Full Text] [Related]
58. Alloantigen-stimulated induction and release of CD30 in patients with end-stage renal failure.
Velásquez SY; Süsal C; Opelz G; García LF; Alvarez CM
Hum Immunol; 2012 Nov; 73(11):1102-8. PubMed ID: 22940451
[TBL] [Abstract][Full Text] [Related]
59. Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation.
Heinemann FM; Rebmann V; Witzke O; Philipp T; Broelsch CE; Grosse-Wilde H
Transplantation; 2007 Mar; 83(6):706-11. PubMed ID: 17414702
[TBL] [Abstract][Full Text] [Related]
60. sCD30, interleukin-1beta-converting enzyme and anti-Annexin V autoantibodies concentrations in heart transplant recipients.
Zeglen S; Zakliczyński M; Nozyński J; Rogala B; Zembala M
Transpl Immunol; 2006 Nov; 16(3-4):227-31. PubMed ID: 17138058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
